NO20012896L - Fremgangsmåte for behandling av cerebral ischemi og anvendelse av erytropoietin eller erytropoietinderivater forbehandling av cerebral ischemi - Google Patents

Fremgangsmåte for behandling av cerebral ischemi og anvendelse av erytropoietin eller erytropoietinderivater forbehandling av cerebral ischemi

Info

Publication number
NO20012896L
NO20012896L NO20012896A NO20012896A NO20012896L NO 20012896 L NO20012896 L NO 20012896L NO 20012896 A NO20012896 A NO 20012896A NO 20012896 A NO20012896 A NO 20012896A NO 20012896 L NO20012896 L NO 20012896L
Authority
NO
Norway
Prior art keywords
erythropoietin
cerebral ischemia
cerebral
pretreatment
ischaemia
Prior art date
Application number
NO20012896A
Other languages
English (en)
Other versions
NO330079B1 (no
NO20012896D0 (no
Inventor
Hannelore Ehrenreich
Christoph Gleiter
Original Assignee
Christoph Gleiter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7891015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20012896(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Christoph Gleiter filed Critical Christoph Gleiter
Publication of NO20012896D0 publication Critical patent/NO20012896D0/no
Publication of NO20012896L publication Critical patent/NO20012896L/no
Publication of NO330079B1 publication Critical patent/NO330079B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO20012896A 1998-12-14 2001-06-12 Anvendelse av erytropoietin for fremstilling av et legemiddel NO330079B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19857609A DE19857609A1 (de) 1998-12-14 1998-12-14 Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
PCT/EP1999/009864 WO2000035475A2 (de) 1998-12-14 1999-12-13 Verfahren zur behandlung von cerebralen ischämien sowie verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien

Publications (3)

Publication Number Publication Date
NO20012896D0 NO20012896D0 (no) 2001-06-12
NO20012896L true NO20012896L (no) 2001-08-14
NO330079B1 NO330079B1 (no) 2011-02-14

Family

ID=7891015

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012896A NO330079B1 (no) 1998-12-14 2001-06-12 Anvendelse av erytropoietin for fremstilling av et legemiddel

Country Status (26)

Country Link
US (1) US7514072B1 (no)
EP (1) EP1140139B2 (no)
JP (2) JP4750947B2 (no)
KR (1) KR100774827B1 (no)
CN (1) CN1187085C (no)
AT (1) ATE253932T1 (no)
AU (1) AU766216C (no)
BG (1) BG65417B1 (no)
BR (1) BR9916197A (no)
CA (1) CA2353553C (no)
DE (2) DE19857609A1 (no)
DK (1) DK1140139T4 (no)
ES (1) ES2211218T5 (no)
HK (1) HK1042655B (no)
HU (1) HUP0104709A3 (no)
ID (1) ID29107A (no)
IL (2) IL143579A0 (no)
MX (1) MXPA01005971A (no)
NO (1) NO330079B1 (no)
NZ (1) NZ541591A (no)
PL (1) PL202483B1 (no)
PT (1) PT1140139E (no)
RO (1) RO121409B1 (no)
RU (1) RU2242991C2 (no)
WO (1) WO2000035475A2 (no)
ZA (1) ZA200104626B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
AU784550B2 (en) * 1999-04-13 2006-05-04 Kenneth S. Warren Institute, Inc., The Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
JP3993560B2 (ja) * 2001-08-30 2007-10-17 ステム セル セラピューティクス インコーポレイテッド 神経幹細胞の分化およびその治療用途
EP1430114B1 (en) 2001-09-14 2012-01-18 Stem Cell Therapeutics Inc. Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
CA2488497A1 (en) * 2002-06-11 2003-12-18 The Burnham Institute Neuroprotective synergy of erythropoietin and insulin-like growth factor
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
BRPI0408829A (pt) * 2003-03-27 2006-04-04 Janssen Pharmaceutica Nv uso de eritropoietina em recuperação de acidente vascular cerebral
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
US7645733B2 (en) 2003-09-29 2010-01-12 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
AU2006297041A1 (en) * 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
WO2007106986A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Dosing regimes for lh or hcg and epo for treatment of neurological disorders
WO2007142288A1 (ja) * 2006-06-07 2007-12-13 The University Of Tokushima エリスロポエチンを用いた虚血性疾患の治療
MY152789A (en) 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
RU2446834C2 (ru) * 2010-06-15 2012-04-10 Елена Александровна Лебедева Способ лечения пострадавших с сочетанной черепно-мозговой травмой
US9956265B2 (en) 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
RU2495688C1 (ru) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии головного мозга в эксперименте
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation
KR20190052855A (ko) 2017-11-09 2019-05-17 대한제당 주식회사 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
ES2127458T3 (es) 1989-11-06 1999-04-16 Cell Genesys Inc Produccion de proteinas utilizando recombinacion homologa.
CA2071989C (en) 1989-12-22 1999-07-27 Scott C. Chappel Endogenous gene expression modification with regulatory element
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
JP3537151B2 (ja) 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
WO1994025055A1 (en) 1993-04-29 1994-11-10 Abbott Laboratories Erythropoietin analog compositions and methods
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
AU784550B2 (en) 1999-04-13 2006-05-04 Kenneth S. Warren Institute, Inc., The Modulation of excitable tissue function by peripherally administered erythropoietin
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Also Published As

Publication number Publication date
HUP0104709A2 (hu) 2002-04-29
ZA200104626B (en) 2002-09-06
CN1335776A (zh) 2002-02-13
RU2242991C2 (ru) 2004-12-27
ID29107A (id) 2001-07-26
MXPA01005971A (es) 2002-03-27
KR100774827B1 (ko) 2007-11-07
NO330079B1 (no) 2011-02-14
EP1140139B2 (de) 2009-03-18
IL143579A (en) 2007-10-31
HUP0104709A3 (en) 2002-05-28
DE59907752D1 (de) 2003-12-18
RO121409B1 (ro) 2007-05-30
WO2000035475A2 (de) 2000-06-22
KR20010082346A (ko) 2001-08-29
US7514072B1 (en) 2009-04-07
PL202483B1 (pl) 2009-06-30
ATE253932T1 (de) 2003-11-15
AU766216B2 (en) 2003-10-09
EP1140139B1 (de) 2003-11-12
BR9916197A (pt) 2001-09-04
DK1140139T3 (da) 2004-03-15
CA2353553A1 (en) 2000-06-22
DK1140139T4 (da) 2009-06-08
PL349335A1 (en) 2002-07-15
ES2211218T3 (es) 2004-07-01
EP1140139A2 (de) 2001-10-10
CA2353553C (en) 2011-05-17
DE19857609A1 (de) 2000-06-15
EP1140139B9 (de) 2004-03-31
ES2211218T5 (es) 2009-06-03
CN1187085C (zh) 2005-02-02
NZ541591A (en) 2007-08-31
PT1140139E (pt) 2004-04-30
AU766216C (en) 2004-11-11
HK1042655A1 (en) 2002-08-23
WO2000035475A3 (de) 2000-10-19
BG65417B1 (bg) 2008-07-31
JP4750947B2 (ja) 2011-08-17
JP2002532432A (ja) 2002-10-02
IL143579A0 (en) 2002-04-21
AU2283100A (en) 2000-07-03
JP2011079860A (ja) 2011-04-21
NO20012896D0 (no) 2001-06-12
HK1042655B (zh) 2005-09-23
BG105575A (en) 2002-01-31

Similar Documents

Publication Publication Date Title
NO20012896L (no) Fremgangsmåte for behandling av cerebral ischemi og anvendelse av erytropoietin eller erytropoietinderivater forbehandling av cerebral ischemi
FI961438A0 (fi) beta-amyloidiproteiinituotannon estäjiä
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
DE3586859D1 (de) Mittel zur behandlung und zum schutz der haut.
NO20060307L (no) Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
ES2157005T3 (es) Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina.
ZA200004260B (en) Treatment of skin disorders.
FR2712811B1 (fr) Procédé pour lutter contre l'adiposite et compositions utilisables à cet effet.
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
AP9801286A0 (en) Therapeutic compounds.
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
HUP0204180A2 (hu) Külsőleges készítmény és alkalmazása allergiás dermatitisz kezelésére
DK0659079T3 (da) Transdermalt terapeutisk system med pentylentetrazol som aktivt stof.
TR200401036T1 (tr) Yüksek kan basıncının tedavisi için citalopram.
SE9901578D0 (sv) New use of substance in PNS
TW200508229A (en) Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees